Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis

An analysis of treatment preferences and sexual quality of life outcomes in female partners of Chinese men with erectile dysfunction

(2016) Han-Zhong Li et al.   ASIAN JOURNAL OF ANDROLOGY

The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction

(2016) Eugenio Ventimiglia et al.   Expert Opinion On Drug Safety

Efficacy of Tadalafil De-Escalation in the Treatment of Psychogenic Erectile Dysfunction

(2016) Guangyu Li et al.   UROLOGIA INTERNATIONALIS

An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy

(2015) Xiao-Feng Wang et al.   ASIAN JOURNAL OF ANDROLOGY

Phosphodiesterase 5 Inhibitors for the Treatment of Erectile Dysfunction: A Trade-off Network Meta-analysis

(2015) Liang Chen et al.   EUROPEAN UROLOGY

A comparison of the available phosphodie­sterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil

(2015) Jeffrey Evans et al.   Patient Preference and Adherence

The prevalence of and risk factors for prostatitis-like symptoms and its relation to erectile dysfunction in Chinese men

(2015) Z. Zhang et al.   Andrology

An epidemiological study of sexual disorders in south Indian rural population

(2015) TS Sathyanarayana Rao et al.   Indian Journal of Psychiatry

Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: results from a randomized, open-label study

(2014) K Hatzimouratidis et al.   INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH

PDE5 Inhibitor Treatment Persistence and Adherence in Brazilian Men: Post-hoc Analyses from a 6-Month, Prospective, Observational Study

(2014) Carlos Cairoli et al.   International Braz J Urol

Comparison of the simplified International Index of Erectile Function (IIEF-5) in patients of erectile dysfunction with different pathophysiologies

(2014) Zhengyan Tang et al.   BMC Urology

A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction

(2013) Amr El-Meliegy et al.   CURRENT MEDICAL RESEARCH AND OPINION

Comparative Effectiveness and Safety of Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction: A Systematic Review and Network Meta-analysis

(2013) JinQiu Yuan et al.   EUROPEAN UROLOGY

An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors

(2013) Roberto Bruzziches et al.   EXPERT OPINION ON PHARMACOTHERAPY

Relationship between erectile function and sexual self-confidence: a path analytic model in men being treated with tadalafil

(2013) A Sontag et al.   INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH

Adherence to Initial PDE5 Inhibitor Treatment: Randomized OpenLabel Study Comparing Tadalafil Once a Day, Tadalafil on Demand, and Sildenafil on Demand in Patients with Erectile Dysfunction

(2013) Jacques Buvat et al.   Journal of Sexual Medicine

A Randomized Open‐Label Trial with a Crossover Comparison of Sexual Self‐Confidence and Other Treatment Outcomes Following Tadalafil Once a Day Vs. Tadalafil or Sildenafil On‐Demand in Men with Erectile Dysfunction

(2012) Eusebio Rubio‐Aurioles et al.   Journal of Sexual Medicine

Efficacy and satisfaction rates of oral PDE5is in the treatment of erectile dysfunction secondary to spinal cord injury: A review of literature

(2012) Nicole Rizio et al.   JOURNAL OF SPINAL CORD MEDICINE

Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation

(2010) Konstantinos Hatzimouratidis et al.   EUROPEAN UROLOGY

Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors

(2009) Joby Taylor et al.   BJU INTERNATIONAL